With a considerable patient population and continued government focus on lowering national smoking rates, the nicotine dependence market represents a lucrative opportunity for pharmaceutical companies. With strong uptake since launch in 2006 of Pfizer's Chantix (varenicline), the seven major prescription nicotine dependence market was estimated to total $1.35 billion in 2008.
Reasons to Purchase
Benchmark key late-stage pipeline nicotine dependence projects against current market leading brands, supported by insight from key opinion leaders.
Quantify the future market landscape with sales forecasts of marketed, generics, and key late-stage pipeline drugs to 2018 in the US, 5EU and Japan.
Understand key events impacting the future nicotine dependence prescription drug market
(0 items)
